Table 1. Key clinical trials for bevacizumab and ramucirumab.
| Trial | Additional agents combined with VEGF monoclonal antibodies | PFS (or TTP) | OS | RR | Notes |
|---|---|---|---|---|---|
| Bev | |||||
| Johnson et al., phase II (19) | Carbo, paclitaxel ± bev | 7.4 vs. 4.2 months (P=0.023) | 17.7 vs. 14.9 months (P=0.63) | 31.5% vs. 18.8% | PFS benefit, not powered for OS |
| ECOG 4599 (20) | Carbo, paclitaxel ± bev | 6.2 vs. 4.5 months (P<0.001) | 12.3 vs. 10.3 months (P=0.003) | 35% vs. 15% (P<0.001) | OS benefit of 2 months |
| AVAiL (21,22) | Cisplatin, gemcitabine ± bev | 6.7/6.5 vs. 6.1 months (P=0.003, 0.03) | 13.6/13.4 vs. 13.1 months (P=0.420, 0.761) | 34%/30.4% vs. 20.1% (P<0.0001, 0.0023) | No OS benefit, not powered for OS |
| AVAPERL (23,24) | Maintenance: pem/bev vs. pem (no bev) | 7.4 vs. 3.7 months (P<0.001) | 17.1 vs. 13.2 months (P=0.29) | 55.5% vs. 50.0% | Not powered for OS |
| POINTBREAK (25) | Carbo/pem vs. carbo/paclitaxel | 6.0 vs. 5.6 months (P=0.012) | 12.6 vs. 13.4 months (P=0.949) | 34.1% vs. 33.0% | Maintenance trial included bev in both arms |
| PRONOUNCE (26) | Carbo/pem (no bev) vs. carbo/paclitaxel/bev | 4.4 vs. 5.49 months (P=0.610) | 10.5 vs. 11.7 months (P=0.615) | 23.6% vs. 27.4% (P=0.414) | Not powered for PFS or OS |
| Ram | |||||
| Camidge et al., phase II (27) | Carbo, paclitaxel + ram | 7.85 months | 16.85 months | 55% | – |
| REVEL (28) | Docetaxel (no ram) vs. docetaxel/ram | 10.5 vs. 9.1 months (P<0.0001) | OS benefit of 1.4 months | ||
VEGF, vascular endothelial growth factor; PFS, progression free survival; TTP, time to progression; OS, overall survival; RR, response rate; bev, bevacizumab; carbo, carboplatin; ECOG, Eastern Cooperative Oncology Group; pem, pemetrexed; ram, ramucirumab.